Drugs / AlloDerm
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT06241196 Comparator | Jul 2022 → Apr 2024 | — | Tanta University | Unknown | No outcome recorded |
| Phase 2 | NCT01834339 Comparator | Sep 2013 → Nov 2014 | — | Stephen E. Feinberg | Terminated | No outcome recorded |
| Phase 4 | NCT07203326 Comparator | Feb 2025 → Aug 2026 overdue | gingival recession | Ohio State University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05565079 Background | Oct 2022 → Oct 2024 | gingival recession | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT04614350 Comparator | Oct 2020 → Feb 2022 | gingival recession | McGuire Institute | Completed | No outcome recorded |
| Phase 4 | NCT02372305 Comparator | Mar 2016 → Dec 2017 | breast neoplasm | University of Arkansas | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloDerm | “24 patients will be treated with a coronally positioned tunnel with AlloDerm RTM with or without the addition of Enamel Matrix Derivative to compare the baseline and 6-month...” NCT05565079 ↗ |
| Modality | Other / unclassified | “acellular dermal matrix (ADM)” PMID 39604639 ↗ Nov 2024 |